History of Bone Grafts in Spine Surgery

Gilad A. Hampel 1, Emre Yilmaz 2, Chrissie Massrey 3, William Clifton 4, Joe Iwanaga 5, Marios Loukas 3, R. Shane Tubbs 5, 6

1. Department of Structural & Cellular Biology, Tulane University School of Medicine, New Orleans, USA 2. Department of Trauma Surgery, Ruhr University, Bochum, DEU 3. Department of Anatomical Sciences, St. George’s University, St. George, GKO 4. Department of Orthopedic Surgery, Columbia Medical Center, New York, USA 5. Department of Neurosurgery, Tulane University School of Medicine, New Orleans, USA 6. Department of Neurosurgery and Ochsner Neuroscience Institute, Ochsner Health System, New Orleans, USA

Corresponding author: Joe Iwanaga, iwanagajoeca@gmail.com

Abstract

Bone grafting replaces damaged or missing bone with new bone and is used for surgical arthrodesis. Patients benefit from a huge variety of bone graft techniques and options for spinal fusions. This article reviews the rich history of bone grafts in surgery with particular emphasis on spinal fusion. During the early years of bone grafting in spine surgery, bone grafts were used on tuberculosis patients, and the structural support of the graft was most the important consideration. Between 1960 and 2000, many advances were made, specifically in the use of bone graft substitutes. The field of bone grafts in spine surgery has evolved rapidly since first described.

Categories: Orthopedics, Trauma

Keywords: surgery, bone graft substitutes, spine, spinal fusion, history, bone graft

Introduction And Background

Bone grafts are widely used in orthopedic surgery, with materials progressively evolving over time from gold plates to advanced molecular approaches harnessing bone morphogenetic proteins (BMP) and stem cells. Bone grafting dates from the Neolithic age, when a Peruvian tribal chief’s frontal bone was repaired with a gold plate [1]. There is some evidence that the Aztecs used wooden sticks to repair bone fractures [1]. Furthermore, two skulls in Ishtkunui were found by Jagharian, an anthropologist who noticed elements of bone grafts within skulls dating back to around 2000 BCE. The first skull he found showed a piece of animal bone that had been inserted into an injured area of a skull, demonstrating very early attempts at xenografting [2]. The first reports of bone grafts in spine surgery in the 20th century began with Hibbs and Albee, who used bone chips from the tibia and transverse processes [3-4]. Such grafts have evolved over the years. More recent examples of bone graft materials include bioactive glass and biologicals such as bone matrix protein. Therefore, this aspect of spine surgery is continuously evolving. Such materials can be osteoinductive, osteogenic, or osteoconductive (Table 1).

| Osteoconductive | Osteogenic | Osteoinductive |
|-----------------|------------|----------------|
| Hydroxyapatite | BMP        | Calcium phosphate |
| Coralline hydroxyapatite | | Calcium sulfate |
| Collagraft | Autograft | Autograft |
| Autograft | | |
| Allograft | | |

**TABLE 1: Various bone substitutes and their ability to act as osteoconductive, osteogenic, or osteoinductive**

BMP: bone morphogenetic protein

In view of the rich history of bone grafts, the purpose of this paper is to highlight the evolution of bone grafts in relation to spine fusion in more detail.

Review
Ancient history

There is evidence of orthopedic surgeries performed in Ancient Egypt (656-535 BCE). Many Egyptians examined after death showed evidence of limb prostheses, as illustrated by the "black leg miracle," a medieval painting depicting a homoplastic transplant of an Ethiopian limb onto the sacristan Justinian [5]. More modern techniques were developed beginning in the 1600s by Job van Meekeren. Meekeren is credited with the first heterologous bone graft procedure in 1668, when he grafted a dog skull fragment into the skull of an injured soldier. When the soldier wanted the graft removed for religious reasons, Meekeren observed the bony fusion. When he looked to see if he could remove the fragment, he noticed it had been fully incorporated into the soldier's skull [6].

Modern history

Sub-periosteal resection was the standard treatment of non-union fusions in the nineteenth century until 1820, when Philips von Walter performed the first autologous bone graft on a skull in Germany [7]. In 1861, Leopold Ollier published "Traite de la regeneration des os," which was the first paper to define the term bone graft. Like Meekeren, Ollier also noticed the importance of the periosteum for osteogenesis [8]. Barth, however, described the importance for bone regeneration of not only the periosteum but also the bone itself and the marrow. The first homologous bone graft was not performed until 1880; William Macewen used the tibia of a child with rickets to treat a child burdened with an infection in his humerus [6]. Phelps (1891) was the first to recognize the importance of vascularization for the success of bone grafting when he took a piece of bone from a dog and transplanted it into a boy's tibia. He kept the dog and the boy attached to each other for two weeks so the blood could circulate between them. This allowed new bone to grow in the boy [9].

Twentieth-century spinal fusion had two brilliant minds at the helm, Russell Hibbs and Fred Albee. These two individuals paved the way for advanced techniques in orthopedic surgery still used today. Originally, spinal fusions were developed to remediate diseased tissue in tuberculosis and to correct mild to extreme spinal deformations from scoliosis. Hibbs and Albee both used bone grafts to achieve union; Hibbs used fragments of the spinous processes and laminae and Albee used grafts from the tibia [10]. Hibbs's interest in the pathology of tuberculosis ultimately led him to find a way to immobilize the diseased tissue of a vertebral column completely once fused, and thus "make development of deformity impossible" [10]. On January 9, 1911, Hibbs performed the first spinal fusion on a boy with spinal tuberculosis. His ingenuity was evident, as he also implemented grafts of the laminae and lateral articulations [10]. He admitted that in very young individuals, grafting from the tibia seemed to be better for preserving aspects of the laminae and lateral spine, presumably because those spines had yet to achieve significant development.

In the same year, Albee successfully harvested tibial bone grafts, incorporating them into the spinous processes of his patients (Figure 1).
A detailed molecular explanation of why autogenous and homogenous grafting material was optimal had not yet been elucidated, but Albee recognized that grafts "derived from the same individual were most trustworthy" [4]. In one case, Albee achieved approximation between the inferior aspects of the superior lamina and the superior aspect of the inferior lamina with a "heavy kangaroo tendon," which progressed to a successful union after chips of the spinous processes were placed across this interface. This was seen at the time as ingenious, interesting, and welcome [10]. Albee suggested that grafting fruit trees was analogous to bone tissue grafting; just as the bark, sap, and wood are firmly approximated to the recipient branch, so there must be an intimate juxtaposition between the graft and recipient bone across the area of contact. Albee noted that the "technique is not difficult because it has to do with plane surfaces" [4]. His thorough understanding of Wolff's law, asserting it to be paramount in achieving successful restoration of the bone's original tensile strength, was apparent in his remark: "the external shape of the bone is the result of functional adaptation, [allowing] bones or grafts in their altered positions and relationships to meet the new and abnormally directed stress thrown upon them" [4].

By 1915, the procedures of Hibbs and Albee had been performed in hundreds of cases, including Farrell's osteoplastic treatments of Pott's disease [3-4]. In 1920, Sheen described a case of a 22-year-old girl with a tuberculous spine. He grafted a six-inch-long tibial graft into her back. The six-month radiographical follow-up showed that "the graft is visible as a long, curved rod rounded at the ends." The author concluded that "there can be no doubt that the graft has maintained its vitality" [11].

In 1921, Radulesco modified Albee's tibial graft procedure by using half of a rib with the periosteum intact [12]. Other materials used for bone grafts included bovine bone by Brown and Kleinberg [13-14]. Additional indications for spinal fusions with grafting were generated, and in 1914 and 1937, the first fusions were performed to correct mechanical conditions (e.g., hemivertebra) and disc herniation, respectively (Figure 2 and Figure 3) [4,10].
FIGURE 2: Illustration showing the first spinal fusion operation performed

The illustration to the far right shows the use of the pieces from the lamina and the scrapings of the lateral articulations.
FIGURE 3: Stages of a spinal fusion with the cutting of the spinous processes and ligamentum flavum, excision of the posterior articular capsules, articular cartilage, and insertion of bone chips (left)

The same procedure in the lumbar spine is shown to the right.

(After Domnisse, 1959)

Petter also used a splintered rib to produce firmer fixation following the destruction of the articular facets, resulting in a larger surface area of graft covering the entire surface of the laminae [15]. The middle of the 20th century saw another advance in autologous and homologous graft procedures: Abbott modified the Cloward interbody fusion by using autologous and homologous grafts from harvested discs of cranial bones (Figure 4) [16].
The anterior approach to the cervical spine was first introduced in the early 1950s [17-19]. In 1952, Bailey and Badgely used an autologous on-lay strut bone graft for anterior decompression and fusion in a patient with a cervical lytic lesion [17].

In 1955, Robinson and Smith reported the first use of a tri-cortical horseshoe-shaped iliac crest graft for anterior cervical discectomy and fusion for spondylosis [19]. In 1959, Boucher mentioned work with the posterior superior iliac spine (PSIS), where the external cortex of the iliac spine was removed, and the inner spongy bone was removed with a curette and replaced in the fusion cavity [20]. Dommisse (1959) also claimed that lumbosacral spine fusions were successful only if both sides of the PSIS were grafted (Figure 5).
FIGURE 5: The process of using cancellous bone from the posterior superior iliac spine for spinal fusion (left). The completed spinal fusion (right).

(After Domnisse, 1959)

He noted that shear strain was a limiting factor that had kept non-union rates high in the past; ensuring maximal contact between graft and graft bed was a crucial detail in establishing fusion [21].

There were many advances in bone grafts between 1960 and 2000, specifically in the use of bone graft substitutes. In 1965, Urist discovered bone morphogenic proteins (BMPs) [21-22], which led to further improvement of growth factor-enhanced absorbable collagen sponges [23]. During the 1970s, porous metals were considered possible bone graft substitutes due to their physical strength [24]. The first use of ceramics for spinal bone grafts was reported in 1979 by Shima et al., where 20 dogs underwent an anterior cervical discectomy and interbody fusion. The first use of ceramics in a human spine was reported in 1991. Hase et al. described the use of ceramic laminae in bilateral open laminoplasty for cervical myelopathy [25]. During the 1990s, the use of ceramics in spine surgery was reported by Ransford et al. in a study that compared ICBG with β-TCP (tricalcium phosphate) [26].

Lindholm et al. analyzed the use of demineralized bone grafts for inducing new bone formation during the 1980s. One of the first reports described the capability of grafts consisting of demineralized bone matrix (DBM) combined with autogenous bone marrow to enhance fusion in the thoracic and lumbar spines of rabbits [27-28]. Since then, DBM has been widely used as a potential bone graft enhancer, extender, or substitute. In 1988, stainless steel interbody cages were introduced [29]. Since then, interbody cage technology has improved to now use polyetherketone, titanium, and carbon fiber-reinforced polymers [30]. Curylo reported the first case of autologous bone marrow aspirate used for posterolateral fusion in a rabbit model in 1999 [31]. Finally, during the early 2000s, tantalum became the first porous metal to be used as an implant in bone grafting [32-33].

Pitfalls of bone grafts

Iliac crest harvest sites are used because they have been shown to have increased expression of natural BMPs, BMP receptors, and other factors important for graft success [34], making them osteogenic, osteoinductive, and osteoconductive. While grafting from the iliac crest has been shown to have many benefits, it also has its pitfalls. Since autografts come from the same individual, they may have complications, including chronic pain from the graft site, decreased sensation in the graft site, infection, and the possibility of hematoma development at the harvest site [35-36]. Additionally, iliac crest bone grafts have been shown to increase donor site morbidity (up to approximately 50%, although this decreases over time) in that they can lead to both an increase in operating time and increased length of stay in the hospital [37-38] as compared to grafts from other body sites. Due to these complications, much research has been done to counteract how much of graft is needed for a successful surgery. Synthetic compounds called extenders are often used as additives to auto/allografts and have been helpful in limiting the amount of graft that needs to be taken from the iliac crest [39-41].
An alternative to the autograft is an allograft in which bone is taken from another person. Allografts are osteoconductive and osteoinductive, however, they lack osteogenic properties, as those cells are lost when the allograft is sterilized. A popular form of allograft in spine surgery is demineralized bone matrix (DBM), so named because the mineralized portion of the bone gets removed once it has been treated with an acid extraction in the sterilization process. This process leads to a decreased amount of growth factors limiting the osteogenic potential of allograft [41]. Thus, BMPs have been developed as a supplement to allografts to help with osteogenicity and create better fusion rates [42]. Allografts are rarely used by themselves, as data suggest that when combined with an autograft, better fusion rates occur [43-44]. Compared to an autograft, an allograft has an even higher risk of infection and rejection. Additionally, while BMPs have been postulated to have a synergistic effect with iliac crest bone grafts [45], there have been doubts regarding the cost-effectiveness of using them [46].

**Present and future of bone grafts in spine fusion**

Neverthless, there have been many recent developments of products and materials to be used as alternatives or additives to bone grafts. Bone graft substitutes, like demineralized bone matrix, are used instead of autografts. However, their potential to be osteoinductive, osteoconductive, and osteogenic is limited. Bone graft extenders are osteoconductive compounds used as additives to auto/allografts to increase bone graft volume and add structural support. Enhancers are compounds that have been developed to help with the fusion of bone grafts [41].

BMPs have been used as carriers for osteogenic growth factors. In 2009, there was a randomized controlled trial that compared the use of one BMP, called rhBMP-2, with iliac crest bone grafts to evaluate fusion rates in a posterior lumbar interbody fusion. The study showed that the rates of fusion were greater than that of the grafts used from the iliac crest [40]. Additionally, those who received iliac crest bone grafts tended to experience more blood loss and longer surgery times [50]. A potential risk of BMP use is paradoxical osteolysis, seroma formation, and recurrence of certain bone cancers.

While autografts remain the mainstay of bone grafting, synthetic bone substitutes and enhancers help combat some of the complications created by autografts. They help decrease donor site morbidity, risk of infection, and inflammation in the recipient tissue. The synthetic materials are constantly being adjusted for proper composition, making them more diverse [41].

The future of bone grafts will continue to develop. New materials are constantly being developed and evaluated. For example, Bhakta et al. took a new graft material made up of silane-modified polycaprolactone-tricalcium phosphate and heparin sulfate glycosaminoglycan, and they looked at the potential osteostimulatory properties in rats [41]. Likewise, Geurts et al. performed an in vitro study that showed support for autologous degenerative facet joint bone grafts to have very comparable osteogenicity to iliac crest bone grafts [42].

Today, patients benefit from a huge variety of bone graft techniques and options for spinal fusions. There are approximately 200,000 to 250,000 spinal fusion procedures in the United States annually [53-55]. Bone grafts are graded according to their ability to provide osteoinductivity, osteoconductivity, and osteogeneticity [35]. The surgeon has to choose according to the risk/benefit profile of patients and consider autograft, allograft, polymer-based, ceramic-based, growth factor-based, and cell-based bone grafts. The bone graft market is growing and is estimated to hit the $2 billion dollar mark in 2023 [56]. New options, such as mesenchymal stem cells (MSC), which can be found in different adult tissues and used as autografts for bony fusions, are gaining more popularity [57]. Nevertheless, despite these promising and interesting new bone graft options, ICBG remains the gold standard.

**Conclusions**

The field of bone grafts is evolving rapidly and is becoming increasingly complex. In the early days of bone grafting in spine surgery, bone grafts were used for tuberculosis patients and the structural support of the graft was the most important consideration. In light of modern research, bone grafts must meet specific criteria for successful implantation, and the spine surgeon must be aware of the risks and benefits of each option in order to provide the best choice for the patient.

**Additional Information**

**Disclosures**
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Urist MR, O’Connor RT, Burwell RG: Bone Graft, Derivatives & Substitutes. Butterworth-Heinemann, Cambridge; 1994.
2. Flati G, Di Stanislao C: Chirurgianella preistoria. Parte I. Provincia Med Aquila. 2004, 2:8-11.
3. Farrell B: Hibbs osteoplastic operation for Pott’s disease. Report of clinical observations with results in one hundred and fifty-eight cases, and interpretation of experimental studies in animals. JAMA. 1915, LXIV:398-400. 10.1001/jama.1915.025703010018006
4. Albee F: The fundamental principles involved in the use of the bone graft in surgery. Am J Med Sci. 1915, 149:513-25.
5. Rinaldi E: Il primo trapianto omoplastico di un artro secondo la leggenda dei santi Cosma e Damiano. G Ital Ortop Traumatol. 1987, 15:405-17.
6. de Boer HJ: The history of bone grafts. Clin Orthop Relat Res. 1988, 292-8.
7. Donati D, Zolezzi C, Tomba P, Viganò A: Bone grafting: historical and conceptual review, starting with an old manuscript by Vittorio Putti. Acta Orthop. 2007, 78:19-25. 10.1080/17456670601031576
8. Putti V: I trapianti ossei. Arch Ortop. 1912, 29:294-334.
9. Phelp AM: Transplantation of tissue from lower animals to man, and a report of the case of bone-transplantation at Charity Hospital, Blackwell’s Island. N.Y. 1891. Clin Orthop Relat Res. 2000, 3-9.
10. Howarth MB: Evolution of spinal fusion. Ann Surg. 1943, 117:278-89. 10.1097/00000658-194302000-00014
11. Sheen AW: Case of tuberculous spine; tibial bone-graft. Proc R Soc Med. 1920, 15:90. 10.1177/003591572001300243
12. Radulesco A: Bone implants in the spine. Presse Med. 1921, 4:284.
13. Brown, L: Beef bone in stabilizing operations of the spine. J Bone Jt Surg 1922, 4:711-50.
14. Kleinberg, S: Unilateral spine fusion. Arch Surg. 1933, 26:1055-42. 10.1001/archsurg.1933.01170060104006
15. Petter C: Rib-splinter graft in spinal fusion for vertebral tuberculosis. J Bone Jt Surg 1937, 19:413-6.
16. Abbott KH: Use of frozen cranial bone flaps for autogenous and homologous grafts in cranioplasty and spinal interbody fusion. J Neurosurg. 1955, 10:380-8. 10.3171/jns.1955.10.4.0380
17. BA RW, BA CE: Stabilization of the cervical spine by anterior fusion. J Bone Joint Surg Am. 1960, 42-A:565-94.
18. Choward RB: The anterior approach for removal of ruptured cervical disks. J Neurosurg. 1958, 15:602-17. 10.3171/jns.1958.15.6.0602
19. Robinson B: Anterolateral cervical disc removal and interbody fusion for cervical disc syndrome. Bull Johns Hopkins Hosp. 1955, 96:223-4.
20. Boucher HH: A method of spinal fusion. J Bone Joint Surg Br. 1959, 41-B:248-59. 10.1002/0301-620X.41B2.248
21. Dommisse GF: Lumbo-sacral interbody spinal fusion. J Bone Joint Surg Br. 1959, 41-B:879-95. 10.1002/0301-620X.41B1.87
22. Urist MR: Bone: formation by autoinduction. Science. 1965, 150:892-9. 10.1126/science.150.3698.895
23. Van der Stok J: Bone Graft Substitutes. Erasmus University, Rotterdam; 2015.
24. White EW, Weiner JN, Roy DM, Owen EL, Chiroff RT, White RA: Replamineform porous biomaterials for hard tissue implant applications. J Biomed Mater Res. 1975, 9:23-7. 10.1002/jbm.820090406
25. Laurencin C, Khan Y, El-Amin SF: Bone Graft, Derivatives & Substitutes. Expert Rev Med Devices. 2006, 3:49-57. 10.1586/17444403.1.1.49
26. Ransford A.O, Morley T, Edgar M.A, et al.: Synthetic porous ceramic compared with autograft in scoliosis surgery. A prospective, randomized study of 541 patients. J Bone Joint Surg Br. 1998, 80:15-18. 10.1002/0301-620X.80B1.0800013
27. Lindholm TS, Nilsson OS, Lindholm TC: Extraskeletal and intraskeletal new bone formation induced by demineralized bone matrix combined with bone marrow cells. Clin Orthop Relat Res. 1982, 251-5.
28. Ragni P, Lindholm TS, Lindholm TC: Vertebral fusion dynamics in the thoracic and lumbar spine induced by allogeneic demineralized bone matrix combined with autogenous bone marrow. An experimental study in rabbits. Ital J Orthop Traumatol. 1987, 13:241-51.
29. Bagby GW: Arthrodesis by the distraction-compression method using a stainless steel implant. Orthopedics. 1988, 11:951-4. 10.3928/0147-7447-19880601-15
30. Smith KA, Russo GS, Vaccaro AR, Arnold PM: Scientific, clinical, regulatory, and economic aspects of choosing bone graft/biological options in spine surgery. Neurosurgery. 2019, 84:827-35. 10.1093/neuros/nyy322
31. Carlylo LJ, Johnstone B, Peterislie CA, Janicki JA, Yoo J: Augmentation of spinal arthrodesis with autologous bone marrow in a rabbit posterolateral spine fusion model. Spine (Phila Pa 1976). 1999, 24:434-8.
32. Bobyn JD, Stackpool GJ, Hacking SA, Tanzer M, Krygier JJ: Characteristics of bone ingrowth and interface mechanics of a new porous tantalum biomaterial. J Bone Joint Surg Br. 1999, 81:907-14. 10.1002/0301-620x.81b6.9285
33. Tsaok AK, Roberton JR, Christie MJ, Dure DD, Heck DA, Robertson DD, Poggie RA: Biomechanical and clinical evaluations of a porous tantalum implant for the treatment of early-stage osteonecrosis. J Bone Joint Surg Am. 2005, 87 Suppl 2:22-7. 10.2106/JBJS.E.00490
34. Takemoto RC, Fajardo T, Kirsch T, Egel KA: Quantitative assessment of the bone morphogenetic protein expression from alternate bone graft harvesting sites. J Orthop Trauma. 2010, 24:564-6.
Bone graft and substitutes market size worth $4.3 billion by 2028

Geurts J, Ramp D, Schären S, Netzer C: Heparan sulfate scaffolds for spinal fusion applications

Bhakta G, Ekaputra AK, Rai B, et al.: Bone graft: should it still be the gold standard for treating iliocrest bone grafts? A preliminary study of the efficacy of beta tricalcium phosphate as a bone expander for posterolateral lumbar fusion. Spine (Phila Pa 1976). 2009, 34:S167-8.

Jorgenson SS, Lowe TG, France J, Sabin J: Autologous iliac crest bone graft: should it still be the gold standard for treating anterior iliac crest bone graft harvesting using the corticocancellous reamer system. J Orthop Trauma. 2001, 15:500-6.

Westrich GH, Geller DS, O'Malley MJ, Deland JT, Hellet DL: Anterior iliac crest bone graft harvesting using the corticocancellous reamer system. J Orthop Trauma. 2001, 15:500-6. 10.1097/00007632-200212010-00005

Dimar JR 2nd, Glassman SD, Burkus JK, Carreon LY: Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976). 2006, 31:2554-9; discussion 2540. 10.1097/01.brs.0000240715.78657.81

Gruskay JA, Basques RA, Bohl DD, Webb ML, Grauer JN: Short-term adverse events, length of stay, and readmission after iliac crest bone graft for spinal fusion. Spine (Phila Pa 1976). 2014, 39:1718-24.

10.1097/BRS.0000000000001476

Vaccaro AR, Whang PG, Patel T, et al.: The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J. 2008, 8:837-45. 10.1016/j.spinee.2007.03.012

Jorgenson SS, Lowe TG, France J, Sabin J: A prospective analysis of autograft versus allograft in posterolateral lumbar fusion in the same patient. A minimum of 1-year follow-up in 144 patients. Spine (Phila Pa 1976). 1994, 19:2048-53. 10.1097/00007632-199409150-00005

Morris MT, Tarpada SP, Cho W: Bone graft materials for posterolateral fusion made simple: a systematic review. Eur Spine J. 2018, 27:1856-67. 10.1007/s00586-018-5511-6

Boden SD, Kang J, Sandhu H, Heller JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976). 2002, 27:2662-73. 10.1097/00007632-200212010-00005

Kang J, An H, Hillbrand A, Yoon ST, Kavanagh E, Boden S: Grafton and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976). 2012, 37:1083-91. 10.1097/BRS.0b013e31823ed817

Vaccaro AR, Patel T, Fischgrund J, et al.: A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976). 2004, 29:1885-92. 10.1097/01.brs.0000137062.79201.98

Giannoudis PV, Kanakaris NK, Dimitriou R, Gill I, Kolimarakas V, Montgomery RJ: The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res. 2009, 467:3259-48. 10.1007/s11999-009-0846-2

Garrison KR, Shemilt I, Donell S, et al.: Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev. 2010, 2010:CD006950. 10.1002/14651858.CD006950.pub2

Egol KA, Nauth A, Lee M, Pape HC, Watson JT, Borrelli J Jr: Bone grafting: sourcing, timing, strategies, and alternatives. J Orthop Trauma. 2015, 29 Suppl 12:S10-4.

2008 Bone grafts and bone substitutes - Orthopedic Network News. (2008). Accessed: December 21, 2021: https://www.yumpu.com/en/document/view/6328775/2008-bone-grafts-and-bone-substitutes-orthopedic-network-news.

Sen MK, Miclau T: Autologous iliac crest bone graft: should it still be the gold standard for treating nonunions? Injury. 2007, 38 Suppl 1:S75-80. 10.1016/j.injury.2007.02.012

Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY: Two-year fusion and clinical outcomes in 224 patients treated with a single-level instrumented posterolateral fusion with iliac crest bone graft. Spine J. 2009, 9:880-5. 10.1016/j.spinee.2009.05.013

Bhakta G, Ekaputra AK, Rai B, et al.: Fabrication of polycaprolactone-silanated β-tricalcium phosphate-heparan sulfate scaffolds for spinal fusion applications. Spine J. 2018, 18:818-30.

10.1016/j.spinee.2017.12.002

Geurts J, Ramp D, Schüren S, Netzer C: Georg-Schmoran-Prize of the German Spine Society (DWG) 2016: comparison of in vitro osteogenic potential of iliac crest and degenerative facet joint bone autografts for intervertebral fusion in lumbar spinal stenosis. Eur Spine J. 2017, 26:1408-15. 10.1007/s00586-017-5020-z

Yoon ST, Boden SD: Spine fusion by gene therapy. Gene Ther. 2004, 11:560-7. 10.1038/sj.gt.3302205

Aghdasi B, Montgomery SR, Daubs MD, Wang JC: A review of demineralized bone matrices for spinal fusion: the evidence for efficacy. Surgeon. 2015, 11:59-68. 10.1016/j.surge.2012.08.001

Boden SD: Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002, 27:S26-31. 10.1097/00007632-200208151-00007

Bone graft and substitutes market size worth $4.3 billion by 2028. (2021). Accessed: December 20, 2021: https://www.grandviewresearch.com/press-release/global-bone-grafts-substitutes-market.

Ellorai AE, Susai CI, Daniels AH: Mesenchymal stromal cells in spinal fusion: current and future applications. J Orthop. 2017, 14:1-3. 10.1016/j.jor.2016.10.010